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Survivin, a key player in cancer progression, increases
in obesity and protects adipose tissue stem cells from
apoptosis
Miriam Ejarque1,2,8, Victòria Ceperuelo-Mallafre1́,2,8, Carolina Serena1,2, Gisela Pachón2,3,4, Yaiza Núñez-Álvarez5,
Margarida Terrón-Puig1, Enrique Calvo1,2, Catalina Núñez-Roa1,2, Wilfredo Oliva-Olivera6,7, Francisco J Tinahones6,7,
Miguel Angel Peinado5, Joan Vendrell*,1,2 and Sonia Fernández-Veledo*,1,2
Adipose tissue (AT) has a central role in obesity-related metabolic imbalance through the dysregulated production of cytokines and
adipokines. In addition to its known risk for cardiovascular disease and diabetes, obesity is also a major risk for cancer. We
investigated the impact of obesity for the expression of survivin, an antiapoptotic protein upregulated by adipokines and a diagnostic
biomarker of tumor onset and recurrence. In a cross-sectional study of 111 subjects classified by body mass index, circulating levels
of survivin and gene expression in subcutaneous ATwere significantly higher in obese patients and positively correlated with leptin.
Within AT, survivin was primarily detected in human adipocyte-derived stem cells (hASCs), the adipocyte precursors that determine
ATexpansion. Remarkably, survivin expression was significantly higher in hASCs isolated from obese patients that from lean controls
and was increased by proinflammatory M1 macrophage soluble factors including IL-1β. Analysis of survivin expression in hASCs
revealed a complex regulation including epigenetic modifications and protein stability. Surprisingly, obese hASCs showed survivin
promoter hypermethylation that correlated with a significant decrease in its mRNA levels. Nonetheless, a lower level of mir-203, which
inhibits survivin protein translation, and higher protein stability, was found in obese hASCs compared with their lean counterparts.
We discovered that survivin levels determine the susceptibility of hASCs to apoptotic stimuli (including leptin and hypoxia).
Accordingly, hASCs from an obese setting were protected from apoptosis. Collectively, these data shed new light on the molecular
mechanisms governing ATexpansion in obesity through promotion of hASCs that are resistant to apoptosis, and point to survivin as
a potential new molecular player in the communication between AT and tumor cells. Thus, inhibition of apoptosis targeting survivin
might represent an effective strategy for both obesity and cancer therapy.
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Obesity has reached epidemic proportions in Western
cultures, and its comorbidities, particularly diabetes and
cardiovascular diseases, are major public health concerns.1
In response to chronic positive energy balance, white adipose
tissue (WAT) expands by increasing the volume of pre-existing
adipocytes (hypertrophy) and by generating new adipocytes
(hyperplasia) through the recruitment of adipocyte progenitor
cells termed adipose-derived stem cells (ASCs).2 Current
nonsurgical options for obesity are largely unsuccessful over
the long term because once hyperplasia occurs the new
adipose cells remain even after weight loss.3,4 Energy
restriction is associated with a decrease in adipocyte cell size
but not in number; thus, the irreversibility of hyperplasia might
explain the ‘yoyo’ effect of easy regain of lost weight.5
Consequently, promotion of adipose tissue (AT) apoptosis to
reduce total fat mass has recently emerged as a promising
therapeutic strategy for the treatment of obesity.6
Intriguingly, epidemiological studies confirm an association
between obesity and several forms of cancer.7 Proposed
mechanisms that link obesity/adiposity to high cancer risk
include obesity-related inflammation and/or adipokine produc-
tion via enhancement of cell proliferation and migration,
and inflammation pathways, which can prompt cancer devel-
opment and metastasis.8 Apoptosis or anti-apoptosis
(cell survival) mechanisms are usually at the crossroads of
the main pathways influenced by dysfunctional adipokine
production in obesity. Local pro-tumorigenic effects of ASCs
have been also highlighted as important in this process, with a
dual role in the dynamics of WAT expansion and in tumor
progression by inducing proliferation and survival of some
cancer cells through the release of angiogeneic and proin-
flammatory factors.9,10 In this context, we have recently shown
that the clinical phenotype exerts a profound influence on the
behavior of ASCs, with enhanced proliferation but impaired
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adipogenic differentiation in ASCs isolated from obese
subjects,11 underscoring the notion that obesity is linked to
defective adipocyte turnover. However, the apoptotic sensitiv-
ity of ASCs in an obese context is unknown.
Survivin is a member of the inhibitor of apoptosis family of
proteins and functions to inhibit apoptosis and promote cell
division.12 Survivin expression is developmentally regulated
in normal tissue, with little expression in most terminally
differentiated tissues. The abnormally high expression of
survivin in cancer cells makes it an attractive anticancer target.
However, accumulating evidence indicates potential functions
for survivin in normal tissues, indicating that survivin expres-
sion is not cancer specific.13 Interestingly, survivin expression
is upregulated by adipokines such as leptin, suggesting that
the molecular effects of adiposity on carcinogenesis might be
mediated by suppression of apoptosis through survivin-
dependent mechanisms.14,15 Moreover, it has been demon-
strated that survivin is regulated by cytokines in lymphocytes
and plays an important role in proliferation and survival of
hematopoietic cells.16
To our knowledge, no studies have examined the impact of
obesity on survivin expression. We hypothesized that an
obese environment could promote survival of the ASC niche
by decreasing its sensitivity to apoptosis via a survivin-
dependent mechanism. We show for the first time that
circulating levels and WAT expression of survivin are
increased in human obesity. Furthermore, we demonstrate
that survivin protein expression is elevated in ASCs isolated
from obese individuals, and protects from apoptosis. These
findings outline a regulatory for survivin as a new player in AT
remodeling with potential impact in the mechanisms linking
obesity/adiposity to increased cancer risk.
Results
Circulating levels and WAT expression of survivin are
elevated in obesity. We first determined whether obesity
impacted the circulating levels of survivin by measuring its
concentration in subjects according to body mass index (BMI)
(clinical and laboratory data summarized in Table 1). Circulat-
ing survivin levels were significantly higher in obese and
morbid obese subjects than in lean subjects (Figure 1a), and
positively correlated with BMI in bivariate analysis (r=0.274;
P= 0.031). A positive association was also found between
serum survivin and both circulating levels of leptin
(r= 0.3487; P= 0.009) and leptin gene expression in sub-
cutaneous AT (SAT) (r=0.471; P= 0.011), which is consis-
tent with studies linking leptin and survivin function in some
tumors.14 We next measured survivin gene expression in SAT
and visceral AT (VAT) depots from the same subjects. In both
lean and obese subjects, survivin expression was signifi-
cantly higher in VAT than in SAT (Figure 1b). We also found a
significant increase in survivin mRNA expression in SAT
across the groups, with morbid obese subjects having the
highest expression (Figure 1b), whereas no differences in
survivin mRNA expression were observed in VAT across the
different groups. Bivariate analysis showed that survivin gene
expression in SAT correlated positively with BMI, insulin,
HOMA-IR, SAT leptin mRNA and leptin serum levels
(Figure 1c) and negatively with HDLc (r=−0.634;
Po0.001). To strengthen the independence of these asso-
ciations as predictors of survivin gene expression, a multiple
regression analysis model was constructed including the
above-mentioned bivariate correlations, adjusting for age and
gender. SAT survivin expression was predicted by BMI and
HDLc (b= 0.036 and β=0.008, Po0.001; b=−0.008 and
β=0.004, P=0.056, respectively; Supplementary Table S1).
To validate the finding of increased survivin gene expression
in SAT from obese subjects, we measured survivin protein
levels by immunoblotting. In accordance with changes in
gene expression, survivin protein expression in SAT was
significantly higher in obese subjects than in lean subjects
(Figure 1d). Collectively, our results demonstrate for the first
time that both circulating concentrations and SAT expression
levels of survivin are increased in human obesity.
Survivin is predominantly expressed in hASCS of obese
subjects. Given that alterations in survivin levels occurred
only in SAT, we focused our attention on this compartment. To
identify survivin-expressing cells within the SAT depot, we
extracted the adipocyte and stromal-vascular fraction (SVF)
from SAT and measured survivin protein expression. Immu-
noblotting analysis of cell lysates showed that survivin was
chiefly expressed in the SVF, with barely detectable levels in
adipocytes (Figure 2a). The stroma surrounding mature
adipocytes is known to contain a heterergeneous population
of cells rich in hASCs, representing approximately 20% of the
Table 1 Anthropometric and biochemical variables
Lean Obese Morbid obese
N 32 41 38
Sex (male/female) (15/17) (16/25) (24/12)
Age (years) 52 (43–55) 54 (48–57) 51 (44–53)
BMI (kg/m2) 23.06 (2.39) 31.53 (1.55)* 40.61 (3.46)*,**
Glucose (mg/dl) 90.50 (82.75–98.50) 104 (96–125)* 91.8 (86.4–102)**
Insulin (μIU/ml) 6.09 (3.77–8.03) 9.00 (6.05–12.68)* 14.22 (11.64–19.44)*,**
HOMA-IR 1.24 (0.76–1.63) 2.20 (1.59–3.19)* 3.25 (2.46–4.90)*,**
Serum leptin (ng/ml) 8.08 (2.8–15.7) 12.63 (7.11–43.05)* 26.10 (15.67–41.70)*
Leptin SAT (arbitrary units) 3.62 (2.06–4.24) 6.77 (4.91–11.27) 84.02 (53.99–124.16)*,**
Abbreviations: BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance index
Data are presented as mean (S.D.) or median (25th–75th), as appropriate. Differences were analyzed by the unpaired t-test (normal distribution) or Mann–Whitney
U-test (data not-normally distributed). *,**Indicates significant differences between the means of the different groups: * versus lean and ** versus obese Po0.05
Survivin in obesity
M Ejarque et al
2
Cell Death and Disease
Figure 1 Obesity increases circulating survivin levels and gene expression in SAT. (a) Survivin levels in serum of subjects classified according to BMI (L= lean, BMIo25;
Ob= obese, 25oBMI435; MOb=morbid obese, BMI435) (n= 32 L, 41 Ob and 38 MOb). *Po0.05 versus lean. (b) Survivin mRNA expression in SATand VAT depots from
lean, obese and morbid obese subjects (n= 32 L, 41 Ob and 38 MOb). *Po0.01 versus lean and #Po0.01 versus obese. (c) Correlation between SAT survivin mRNA
expression and BMI, insulin, HOMA-IR, SAT leptin gene expression, serum leptin and HDLc. (d) SAT survivin protein levels in obese and lean subjects. *Po0.01 (n= 8 lean and
8 obese). Data information: All values are expressed as mean value±S.E.M. Statistical analyses: For (a and b), ANOVA with post hoc Scheffe correction; for (c), Spearman’s
correlation analysis, and for (d), unpaired Student’s test
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Figure 2 Survivin is predominantly expressed in obese hASCs and is influenced by the inflammatory environment. (a) Survivin protein expression and quantification in total adipose
tissue (AT), adipocyte fraction (AD) and stromal-vascular fraction (SVF) from SATof lean and obese patients. Fumarylacetoacetase (FAA) was used as a loading control. Ponceau S staining
is also provided. *Po0.001 versus total ATand AD. (b) Survivin and p53 protein levels and quantification in hASCs from lean and obese patients. GAPDH was used as a loading control.
*Po0.01 versus lean. (c) Survivin secreted levels and quantification in medium from lean- and obese-derived hASCs. Ponceau S staining was used to check loading. *Po0.05 versus lean
conditioned medium. (d) Total cell extracts of lean- and obese-derived hASCs were subjected to immunoblotting with antibodies against apoptotic and antiapoptotic markers and GAPDH
was used as a loading control. No significant differenceswere found. (e) Lean hASCswere cultured in RPMImedium (C: control) or for 24 h in conditionedmedium (CM) frommacrophages
(M0, M1 and M2) and cells were subjected to immunobloting with survivin and GAPDH antibodies. *Po0.05 versus CM from control, and M0; #Po0.05 versus M2. (f) Left panel, lean
hASCs were cultured in RPMI medium (C: control) or RPMI supplemented with IL-1β (IL1B) or IL-1 β and IL-1 β receptor antagonist (a); right panel, with CM of M1 macrophages or CM of
M1 and IL-1β receptor antagonist (a). Survivin protein levels were measured and GAPDH was used as a loading control. Quantification of three experiments is shown. *Po0.05 versus
control (c); #Po0.05 as indicated in figure. Data information: Values are expressed as mean±S.E.M. Statistical analysis: unpaired Student’s t-test. n= 3–4 patients for each group
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SVF. We therefore evaluated survivin protein expression in
subcutaneous hASCs isolated from lean and obese subjects.
Survivin expression was significantly higher in obese- than in
lean-isolated hASCs (Figure 2b). Consistent with the
described survivin-p53 regulatory axis,17 high levels of
survivin protein in obese-isolated hASCs were accompanied
by significantly lower levels of p53 (Figure 2b). Furthermore,
significantly higher amounts of survivin were detected in
conditioned medium (CM) from cultured obese-isolated
hASCs than in equivalent CM from lean-isolated hASCs,
suggesting greater secretion (Figure 2c). A modest but
nonsignificant increase in the expression of t-BID and
caspase-3 proteins was also detected in obese hASCs
(Figure 2d, top panel), similar to that described in obese
WAT.18,19 No differences were detected in the expression of
other pro-apoptotic (Figure 2d, top panel) or antiapoptotic
(Figure 2d, bottom panel) markers.
We next questioned whether the local proinflammatory
environment characteristic of AT in the obese state might
underlie survivin protein overexpression in obese hASCs.
Thus, we explored the effect of secreted factors of both
proinflammatory M1 and anti-inflammatory M2 macrophages
for survivin expression. To do this, THP-1 cells were polarized
to an M1 or an M2 phenotype as described in Materials
and Methods and CM was collected and used to culture
lean-derived ASCs for 24 h. Survivin expression was signifi-
cantly higher in hASCs cultured in CM from proinflammatory
M1 than in CM from M2 or M0 macrophages (Figure 2e),
suggesting that survivin could be regulated by M1 macro-
phage soluble factors. Indeed, treatment of lean-derived
hASCs with the proinflammatory cytokine IL-1β was suffi-
cient to enhance survivin expression, which was blocked by
the IL-1β receptor antagonist (IL-1RA) (Figure 2f, left panel).
Consistent with a role for IL-1β in survivin upregulation,
M1-induced survivin expression in lean hASCs was
blunted in cells co-treated with IL-1RA (Figure 2f, right panel).
Taken together, these results suggest that macrophage–
ASC crosstalk in obese AT controls the homeostasis and
properties of adipocyte precursors, at least for apoptosis
susceptibility.
Obesity regulates survivin expression in hASCs by
epigenetic, post-transcriptional and post-translational
mechanisms. Notwithstanding the finding that IL-1β
secreted by M1 macrophages might be at least partly
responsible for the increased levels of survivin in obese-
derived hASCs, the fact that levels were maintained during
routine culture of hASCs (Figure 2b), when the inflammatory
signal is no longer present, suggested changes in the
epigenome, which are relatively persistent. We hypothesized
that obese-derived hASCs are obesity conditioned by
epigenetic modifications; specifically, that obesity-linked
hypomethylation of the survivin promoter was responsible
for its overexpression in obese hASCs. Accordingly, we
analyzed the methylation status of the 5´untranslated region
of exon 1 of the survivin gene in hASCs isolated from lean
and obese subjects. Contrary to our expectation, methylation-
specific PCR and pyrosequencing revealed that the survivin
promoter was hypermethylated in obese-derived hASCs
(Figure 3a). A similar association has been detected in
endometrial tumors where DNA methylation is related to
inhibition of p53-mediated repression of survivin.20 Never-
theless, we found that survivin promoter hypermethylation in
obese-derived hASCs was accompanied by a significant
decrease in the levels of its mRNA (Figure 3b), indicating that
additional regulatory mechanisms should exist to explain the
high levels of survivin protein in hASCs from obese subjects.
Given the discrepancy between mRNA (Figure 3b) and
protein expression (Figure 2b), we sought to analyze
potential differences in the expression of the miRNAs
miR-218, mi-R203 and miR-708, which are among the best
known miRNAs to target survivin.21 We observed that
whereas the expression levels of miR-218 and miR-708 were
unchanged between lean- and obese-derived hASCs, the
level of miR-203 was significantly decreased in obese-
derived hASCs (Figure 3c). Considering that miRNAs bind
to the 3´UTR of survivin mRNA and alter protein translation,
the finding of reduced miR-203 expression correlates well
with enhanced survivin protein expression and is consistent
with a number of studies in cancer cell lines.22 To confirm that
survivin is a direct target of miR-203 in our cellular system,
we analyzed the effect of miR-203 on survivin protein
expression in SGBS cells, a well-established human pre-
adipocyte cell line.23 Survivin protein expression was
significantly reduced in cells transfected with an miR-203
mimic, whereas an miR-203 inhibitor significantly increased
survivin protein levels (Figure 3d). Because regulation of
survivin expression is complex and also occurs at post-
translational levels,24 we also explored protein stability. Using
cycloheximide (CHX) to block de novo protein synthesis, we
measured the steady-state levels of survivin protein in obese-
and lean-derived hASCs. Immunoblotting analysis revealed
altered kinetics of protein stability depending on the donor
tissue, with greater survivin protein stability in obese-derived
hASCs (Figure 3E). As previously observed for other
proteins,26–28 CHX treatment provoked an early increase in
steady-state levels of survivin both in obese and lean hASCs;
the origin of this is unknown. Survivin can be degraded via
the ubiquitin–proteasome pathway and is turned over rapidly
with a half-life of about 30 min.25 Levels of ubiquitinated-
survivin were higher in lean hASCs than in obese hASCs
(Figure 3f), suggesting that an obese environment regulates
the steady-state levels of survivin through the proteasomal
degradation pathway. Unexpectedly, treatment of lean-
derived hASCs with MG132, an inhibitor of the ubiquitin–
proteasome system, failed to block degradation of survivin
(Figure 3g). By contrast, the autophagy inhibitor
3-methyladenine (3-MA) stabilized survivin protein, pointing
to a potentially important role for the autophagy-dependent
degradation pathway for survivin protein stability. Other
protein-ubiquitin conjugates have likewise been described
as target proteins for proteasome-independent degradative
pathways.29 Overall, our results demonstrate that obesity
determines survivin protein levels in hASCs via several
mechanisms that would be most likely controlled by an
epigenetic signature associated with the obese environment.
Survivin levels determine apoptosis sensitivity of
hASCs. Similar to other adult stem cell niches, self-
renewal and apoptosis of hASCs represent major processes
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Figure 3 Survivin is regulated at several levels. (a) Hierarchical clustering analysis of DNA methylation levels shows higher ratios of methylation on the survivin promoter from
obese-derived hASCs. (b) Survivin mRNA expression in hASCs from lean and obese donors. ***Po0.001 versus lean. (c) Survivin expression regulated by specific miRNAs binding to
the 3′-UTR of survivin mRNA. *Po0.05 versus lean. (d) hASCs were treated with a mimic (mim203) or inhibitor (inh203) of miRNA-203 and cell lysates were subjected to
immunoblotting against survivin and GAPDH. A representative blot and densitometry analysis of three independent experiments performed are shown. *Po0.05; **Po0.01 versus
control. (e) hASCs were treated with 50 μg/ml cycloheximide (CHX). At the indicated time, cells were lysed and equal amounts of protein were subjected to immunoblotting with anti-
survivin and anti-GAPDH antibodies. A representative blot and the densitometry analysis of three independent experiments performed are shown. (f) hASCs cells from lean and obese
patients were lysed and immunoprecipitated with an anti-survivin antibody or IgG control. Immunoprecipitates were analyzed by immunoblot using anti-ubiquitin antibody (anti-Ub).
Survivin was used as a loading control. Image is representative of three independent experiments. (g) Lean hASCs were pre-treated with MG132 or 3-MA before cycloheximide (CHX)
treatment. At the indicated hours of CHX incubation, cells were lysed and equal amounts of protein were subjected to immunoblotting with anti-survivin and anti-GAPDH antibodies. A
representative blot and the densitometry analysis of three independent experiments performed are shown. *Po0.05 versus MG132. Data information: Values are expressed as
mean±S.E.M. Statistical analysis: Student’s test. n= 3–4 patients for each group
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that determine in vivo maintenance and AT mass.30 Our
previous studies revealed that the microenvironmental niche
triggers intrinsic alterations in the biology of hASCs that affect
their proliferation and differentiation;11,31,32 however, their
apoptotic susceptibility has not been studied to date. Given
that survivin functions as an anti-apoptosis protein, we
evaluated the sensitivity of hASCs to apoptosis induced by
hypoxia and leptin, two recognized obesity-related apoptotic
stimuli in AT.33–35 As anticipated, basal apoptosis was not
significantly different between obese- and lean-isolated
hASCs cells (Figure 4a), as previously reported.30 Both
hypoxia and leptin significantly increased the number of
apoptotic cells in lean- but not in obese-derived hASCs, as
detected by double staining with annexin V and propidium
iodide (Figure 4a). At the protein level, leptin increased
survivin levels in lean but not in obese hASCs, where the
levels were already high under basal conditions (Figure 4b).
Additionally, the level of caspase-3 cleavage, as evaluated by
immunocytochemistry (Figure 4c) and immunoblotting
(Figure 4d), was also higher in leptin-treated lean-isolated
hASCs than in equivalent obese-isolated cells. Thus, our
results not only provide the first evidence that leptin induces
apoptosis of hASCs, which differs from data on murine
3T3-L1 preadipocytes,36 but also reveal a general protection
from apoptosis in obese hASCs. Finally, we explored whether
survivin expression was linked to the suppression of
apoptosis in hASCs. We first treated hASCs isolated from
obese donors with YM155, a small-molecule transcriptional
repressor of survivin,37 and we evaluated apoptosis in cells
treated with leptin. Surprisingly, YM155 treatment failed to
sensitize obese hASCs to the pro-apoptotic effects of leptin
(Supplementary Figure 1A), most likely because YM155 did
not decrease survivin protein expression, whereas mRNA
levels were progressively reduced in a dose-dependent
manner (Supplementary Figure 1B). Nevertheless, adeno-
virus-mediated overexpression of survivin (Figure 5a)
resulted in the suppression of apoptosis in leptin-treated
lean-derived hASCs (Figure 5b), mimicking the phenotype of
obese-derived hASCs. Conversely, adenovirus-mediated
overexpression of dominant-negative survivin (T34A muta-
tion) (Figure 5c) in an obese context increased the sensitivity
to leptin-induced apoptosis, essentially reverting the obese
phenotype (Figure 5d).
Overall, our data demonstrate that survivin regulates
sensitivity to apoptosis of hASCs. Because of its differential
expression in hASCS from lean and obese subjects, survivin
might represent a promising drug target for inhibition of AT
expansion.
Discussion
It has been proposed that the inability of AT to adequately
expand triggers adipocyte apoptosis, a key initial event that
contributes to macrophage infiltration and the chronic
low-grade inflammatory state characteristic of obesity, in turn
creating a pro-apoptoticmilieu inATofobese patients. However,
it is evident that fat mass expansion in WAT is not prevented in
obese patients2 and, in fact, the increase in cell numbers
characteristic of hyperplastic obesity contributes to the enlarge-
ment of fat stores in advanced obesity.38 We hypothesized that
the obese environment promotes survival of the adipocyte
precursors not only by increasing their proliferation rate11 but
also by decreasing their sensitivity to apoptosis. Specifically, we
demonstrate that hASCs are involved in the apoptotic
resistance of AT in obesity, in part via epigenetic regulation of
survivin expression, a key regulator of apoptosis with an
important role in tumor expansion. Furthermore, we provide
evidence that levels of local and systemic survivin are regulated
in obesity, and we identify a close relationship between survivin
and leptin, an adipokine associated with a damaging inflam-
matory and antiapoptotic environment that favors tumor growth
and cancer progression.39
It was the prevailing view that blockade of apoptotic cell
death would reduce AT inflammation and the metabolic
consequences of obesity.40 However, induction of massive
adipocyte-specific apoptosis induces the infiltration of alter-
natively activated M2 macrophages, but not of proinflamma-
tory M1 macrophages, which are characteristic of obese AT.41
Along this line, recent studies reveal that increasing the rate of
programmed adipocyte death reduces the number of adipo-
cytes and prevents diet-induced obesity and further weight
gain under a positive energy balance.6 Collectively, these
results suggest that not only mature adipocytes but also their
precursors are critical in this equilibrium. In this regard, we
have recently shown that an obese environment increases the
proliferative potential of hASCs,11 which might encourage
adipocyte turnover through promotion of the hASC niche. In
the present work, we have discovered a new mechanism that
may go some way to help understand the events that take
place in AT in the context of obesity, namely survivin-mediated
hASC resistance to apoptotic cell death in obese subjects.
Thus, obesity increases the adipocyte progenitor pool by
increasing cell proliferation and inhibiting apoptosis. Although
one might think that this would be an ideal scenario for
promoting SAT expansion, which has been proposed as a
viable therapeutic strategy to improve glucose homeostasis
and insulin resistance,42 the obese environment in this depot
is also associated with restricted adipogenesis.11,43 There-
fore, we propose that in an obesogenic context, the
maintenance of SAT homeostasis is altered as a consequence
of intrinsic defects in hASCs.
Many of the characteristics attributed to hASCs from an
obese phenotype reproduce the behavior of tumor cells:
robust proliferation,11 apoptotic resistance (this study) and an
invasive phenotype.32 Interestingly, the antiapoptotic effects of
some adipokines have been highlighted as a mechanism of
cell survival promoting cancer progression. Recent findings
have shown a strong relationship between adipocyte-derived
leptin and breast cancer.44 Notwithstanding the fact that leptin
might act centrally to trigger apoptosis in WAT resulting in
adipocyte depletion,45–47 several studies suggest that the
molecular effects of leptin on carcinogenesis are mediated by
suppression of apoptosis through survivin-dependent
mechanisms.14,15 Chronically high levels of leptin in obesity
can lead to leptin resistance,48 which results not only in loss of
appetite control but also in resistance to adipocyte apoptosis.
Importantly, we show here that circulating survivin levels are
increased in obesity, and are positively correlated with
circulating leptin. Survivin has been implicated both in
suppression of cell death and regulation of mitosis and is
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found in several subcellular locations such as mitochondria,
cytoplasm, nucleus and the extracellular space.49 Higher
circulating levels of survivin have been detected in patients
with prostate and pancreatic cancer50,51 and in patients with
rheumatoid arthritis.52 The source of extracellular survivin is an
intriguing but unsolved question; however, the increased
expression observed in SAT from obese patients leads us to
speculate about an adipose origin. Specifically, our study reveals
that survivin is predominantly expressed in hASCs, which
concurs with previous studies that define a role for survivin in
regulating the function of hematopoietic progenitor cells.16,53,54
Our data clearly establish that the levels of survivin in hASCs
determine the susceptibility of these cells to apoptotic stimuli.
Survivin has been proposed as a key node protein involved
in adaptation to unfavorable environments since it assists in
protecting cells from stresses such as hypoxia, imbalanced
pH, and alteredmetabolic and redox states commonly found in
the microenvironment of tumors.55 Therefore, it is not
unreasonable to assume a function for survivin in hASCs,
especially in hASCs from an obese environment. Extracellular
survivin might be significant for the pathogenesis of inflamma-
tion as previously reported in human leukocytes in the context
of autoimmune arthritis56 or asthmatic pregnancy.57 In its
extracellular context, survivin modulates T-cell responses,
skewing immunity towards a Th2 response58 similar to the
phenotype observed in obese patients where leptin resistance
is developed.59 Moreover, downregulation of survivin results in
a decrease of IL-6 production by humanmonocytes.60 Overall,
an additional function of survivin in modulation of inflammatory
state in obesity should not be ruled out.
Nonetheless the proinflammatory microenvironment of AT
in obesity may be sufficient to explain the increased levels of
survivin in hASCs. In fact, the higher levels of survivin in VAT
compared with SAT depots, particularly in lean subjects, might
Figure 4 Obese hASCs are resistant to apoptotic stimuli. (a) Flow cytometry analysis of annexin V+propidium iodide (PI) staining in hASCs from lean and obese subjects
treated with different apoptotic stimuli for 48 h. Left panel, representative dot-blots of the different conditions analyzed. Right panel, quantification of % apoptosis over basal
(untreated cells) by annexinV staining. Data were normalized to their controls. *Po0.05 versus lean. (b) Survivin protein levels in leptin-treated hASCs from lean and obese
patients. GAPDH was used as a loading control. (c) Immunofluorescence staining for cleaved caspase-3 (green) and DAPI (blue) in hASCs. (d) Total cell extracts of lean- and
obese-derived hASCs were subjected to immunoblotting with anti-cleaved caspase-3, showing increased caspase-3 levels in lean hASCs treated with leptin for 48 h. Data
information: Values are expressed as mean±S.E.M. Statistical analysis: Student’s t-test. n= 3 for each group
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Figure 5 Survivin levels determine apoptotic sensitivity of hASCS. (a) Lean hASCS were infected with recombinant adenovirus expressing HA-tagged survivin (Ad-Surv).
Different titrations of the recombinant survivin adenovirus were assessed to establish the best concentration to be used. A representative immunoblot is shown. (b) Lean hASCs
were infected with Ad-control or Ad-survivin and 16 h after infection, cells were incubated with or without leptin for 48 h followed by annexin V+propidium iodide (PI) staining and
flow cytometry. Left panel, quantification of annexinV staining. *Po0.01 versus control; #Po0.05 versus Leptin. Right panel, representative dot-blots of the different conditions
analyzed. (c) Obese hASCS were infected with a recombinant adenovirus expressing a mutated survivin protein (Ad-T34A). A representative immunoblot is shown. (d) Obese
hASCs were infected with Ad-control or Ad-T34A and 16 h after infection, cells were incubated with or without leptin for 48 h followed by annexin V+propidium iodide (PI) staining
and flow cytometry. Left panel, quantification of annexinV staining. *Po0.01, **Po0.001 versus control; #Po0.001 versus Leptin. Right panel, representative dot-blots of the
different conditions analyzed. Data information: Values are expressed as mean± S.E.M. Statistical analysis: Student’s t-test. n= 3 patients for each group
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be the result of the basal inflammatory state characteristic of
visceral depots where an increased expression of proinflam-
matory cytokines such as IL-1β was detected (Supplementary
Figure S2). However, the maintenance of these levels ex vivo
points to obesity-induced epigenetic changes of the survivin
gene. Our data also show that the obese microenvironment in
SAT determines survivin protein levels in hASCs via several
mechanisms including post-transcriptional and post-
translational control of gene expression, as previously reported
in cancer cell lines.21 Although several strategies have been
developed to target survivin in cancer therapy,61 our study in
hASCs suggests that simply turning off the survivin transcrip-
tionalmachinery will not be sufficient to decrease survivin levels
and increase the apoptotic sensitivity of obese hASCs. The
differential expression of survivin in obese- and lean-isolated
hASCs is a strong rationale for development of survivin-based
obesity therapeutics targeting the ASC niche.
Although further studies will be required to fully understand
the role of survivin in AT, our findings open a new perspective on
AT dynamics, where survivin might act as a nodal protein
controlling apoptosis and inflammation. They may also help to
unravel the regulatory pathway governing crosstalk betweenAT
and tumor cells. Thus, inhibition of apoptosis targeting survivin
might represent an effective strategy both for obesity and
cancer therapy.
Materials and Methods
Study selection and sample processing. One hundred and eleven
subjects were recruited by the Endocrinology and Surgery departments at the
University Hospital Joan XXIII (Tarragona, Spain). All subjects were of Caucasian
origin and reported that their body weight had been stable for at least 3 months
before the study. They had no systemic disease other than obesity, and all had been
free of infection in the previous month before the study. Primary liver disease,
cardiovascular disease, arthritis, acute inflammatory disease, infectious disease,
neoplasic and renal diseases were specifically excluded by biochemical work-up.
Subjects were classified by BMI according to World Health Organization criteria as
lean, obese and morbid obese. Subjects were stratified according to age, gender
and BMI. The hospital ethics committee approved the study and informed consent
for biobanking surgically removed tissue was obtained from all participants in
accordance with the Declaration of Helsinki. All patients had fasted overnight before
collection of AT and blood. VAT and SAT were obtained from the same individual
during scheduled non-acute surgical procedures including laparoscopic surgery for
hiatus hernia repair or cholecystectomies in non-morbid obese population. Samples
from morbid obese subjects were obtained during bariatric surgery. AT samples
were washed in PBS and immediately frozen in liquid N2 with storage at − 80 °C, or
used immediately for fractionation. For AT fractionation, fresh AT was diced into
small pieces (10–30 mg), washed in PBS and incubated in Medium 199 (Gibco,
Gran Island, NY, USA) plus 4% BSA and 2 mg/ml collagenase type I (Sigma-
Aldrich, St. Louis, MO, USA) for 1 h in a shaking water bath at 37 °C. Adipocytes
were separated by filtration through a 200-μm mesh fabric (Spectrum Laboratories,
Rancho Domínguez, CA, USA) and centrifugation for 5 min at 1500 × g. Buoyant
adipocytes were carefully removed from the top layer and the pellet consisted of
stromal-vascular cells.
Blood analysis. Blood samples were drawn after a 12-h fast, before surgery.
Serum was separated and immediately frozen at –80 °C. Serum biochemical
parameters were measured in duplicate. Serum glucose, cholesterol, HDL
cholesterol and triglycerides were measured by standard enzymatic methods
(Randox Laboratories Ltd, Antrim, UK). Insulin was measured with an
immunoradiometric assay (BioSource International, Camarillo, CA, USA). The
HOMA-IR was calculated from fasting insulin and glucose using the following
equation: HOMA-IR= fasting insulin (μIU/ml) × fasting glucose (mol/l)/22.5. Serum
survivin was measured by a sandwich ELISA (R&D Systems, Minneapolis, MN,
USA). The assay sensitivity was 1.58–9.96 pg/ml and the intra- and inter-assay co-
efficients of variance (CVs) were less than 5.5 and 9.5%, respectively.62 Serum
leptin was measured by ELISA (R&D Systems). The minimum detectable
concentration of human leptin is typically less than 7.8 pg/ml and the intra- and
inter-assay CVs were less than 3.3 and 5.4%, respectively.
Cell culture and treatments. hASCs were isolated from ATof lean and obese
patients from a subsample of patients (donor information summarized in Table 2)
following published protocols. After isolation, the minimal functional and quantitative
criteria established by the International Society of Cell Therapy (ISCT) and the
International Federation for Adipose Therapeutics and Science (IFATS) were routinely
confirmed by flow cytometry as described (Supplementary Figure S3).32 All
experiments were performed in cells at passages 3–7. Cells were cultured in
DMEM/F12 medium containing 10% FBS and 1% antibiotic/antimycotic (penicillin,
streptomycin and fungizone) at 37 °C in a humidified incubator (21% O2 and 5% CO2).
For hypoxia experiments, cells were cultured in a modular incubator with 2% O2, 93%
N2 and 5% CO2 during 48 h. Adenovirus expressing wild type or T34A-mutated
survivin63 was added to 2 × 105 cells in a 35-mm plate at a multiciplity of infection of 50,
followed by incubation for 2 h at 37 °C in Opti-MEM Medium (Gibco). An empty
adenovirus was used as a control. After incubation, adenovirus-containing medium was
replaced with standard culture medium. Twenty-four hours later, cells were treated with
8 μg/ml leptin (Peprotech, Offenbach, Germany) for 24− 48 h to induce apoptosis. To
inhibit survivin expression, obese-derived hASCs were cultured with 20 nM of YM155
(Calbiochem, La Jolla, CA, USA) a potent survivin inhibitor,37 prior to leptin treatment.
Since YM155 is highly toxic and might trigger cell death, dose and timing was empirically
determined by mRNA analysis of survivin. The human acute monocyte leukemia cell line
THP-1 was obtained from the ATCC (Rockville, MD, USA) and cultured as described.64
Briefly, to obtain macrophages, cells were cultured in RPMI-1640 medium supplemented
with 10% FBS, 1% antibiotic/antimycotic and 0.1 μg/ml phorbol myristate acetate (PMA;
Sigma) in a humidified incubator at 37 °C with 5% CO2 for 72 h. Adherent cells (M0
macrophages) were then cultured in the same medium but without PMA for 24 h. M0
macrophages were polarized to M1 or M2 macrophages with 250 ng/ml LPS (Fluka,
Buchs, Switzerland) or 50 ng/ml IL-4 (Peprotech), respectively, overnight (Supplementary
Figure S4). Conditioned medium was collected after 48 h.
miRNA mimic and inhibition assays. miR-203a-3p mimic or miR-203a-
3p hairpin inhibitor (50 nM) (GE Dharmacon, Chicago, IL, USA) or their respective
controls were transfected into SGBS cells using Lipofectamine 3000 (Invitrogen,
Carlsbad, CA, USA). Cells were incubated at 37 °C, 5% CO2 for 48 h and harvested
for analysis.
Gene expression analysis. Total RNA was extracted from AT/cells using the
RNeasy Lipid Tissue Midi Kit (Qiagen, Hilden, Germany). miRNA and RNAso200
nucleotides were isolated from hASCs using the miRNeasy Mini kit (Qiagen). Total
RNA quantity was measured at 260 nm and purity was assessed by the OD260/
OD280 ratio. For gene expression analysis, 1 μg of RNA was reverse transcribed
with random primers using the Reverse Transcription System (Applied Byosistems,
Foster City, CA, USA). For miRNA analysis, cDNA synthesis was performed with the
TaqMan MicroRNA Reverse Transcription Kit (ThermoFisher Scientific, Waltham,
MA, USA). Real-time PCR (qPCR) was conducted on a 7900HT Fast Real-Time
PCR System using TaqMan Gene Expression Assays (Applied Biosystems) for
survivin (Hs 00426651_m1), leptin (Hs00174497_m1) and specific Taqman probes
for hsa-miR-203, hsa-miR-218 and hsa-miR-708. Results were calculated using the
comparative Ct method (2-ΔΔCt) and expressed relative to the expression of the
housekeeping genes cyclophilin 1A (PPIA) (Hs 04194521_s1), 18 S (Hs
03928985_g1) and RNU48 (for miRNA analysis).
Protein expression analysis. Cells were lysed in RIPA buffer containing a
protease inhibitor cocktail (Sigma-Aldrich) and equal amounts of protein were
separated on SDS-PAGE gels, transferred to Immobilon membranes and blocked.
Immunoreactive bands were visualized using SuperSignal West Femto chemilumi-
nescent substrate (Pierce, Rockford, IL, USA) and images were captured using the
VersaDoc imaging system and Quantity One software (Bio-Rad, Hercules, CA, USA).
The following antibodies diluted 1:1000 were used: anti-survivin (ab76424; Abcam,
Milton, Cambridge, UK); anti-BIM and anti-Bclx (559685 and 610211, respectively; BD
Pharmingen, San Diego, CA, USA); anti-BAX and anti-cleaved caspase-3 (#2772 and
#9664, respectively; Cell Signaling Technology, Beverly, MA, USA); anti-tBID and anti-
FLIP (AF860 and AF821, respectively; R&D Systems); anti-GAPDH (MA5-15738;
Sigma-Aldrich); anti-FAA and anti-Ub (sc-66223 and sc-8017, respectively; Santa
Cruz Biotechnology, PaloAlto, CA, USA). Secondary peroxidase-conjugated
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antibodies diluted 1:2000 were as follows: anti-goat (HAF109; R&D Systems), anti-
rabbit and anti-mouse (NA934 and NXA931, respectively; GE Healthcare, Chicago, IL,
USA) and anti-chicken (ab131366; Abcam).
Protein stability. Protein stability assays employing 50 μg/ml cycloheximide
(CHX) (Sigma) to inhibit de novo protein synthesis were performed as described.25
Cell lysates were subjected to SDS-PAGE and immunoblotting with an anti-survivin
antibody (Abcam). For proteasome inhibition, 25 μM of MG132 (Calbiochem) was
added 1 h before CHX. For autophagy-dependent protein degradation assay, 5 mM
3-MA was added 4 h before CHX.
Immunoprecipitation assays. Cell lysates containing equal amounts of
protein (200–400 μg) were immunoprecipitated with anti-survivin antibody (Abcam)
overnight at 4 °C. Immune complexes were precipitated with protein A/G-agarose
beads (Sigma-Aldrich) for 4 h at 4 °C. Immunoprecipitates were separated by
SDS-PAGE and immunoblotted.
Immunocytochemistry. hASCs grown on coverslips were fixed with 4% (w/v)
paraformaldehyde, rehydrated with 2% (v/v) fish skin gelatin and permeabilized with
0.2% Triton X-100 prior to incubation with 5% (v/v) goat serum. Subsequently, cells
were incubated overnight at 4 °C with anti-cleaved caspase-3 antibody (Cell Signaling
Technology) in PBS containing 1% goat serum. Coverslips were washed with PBS
and incubated for 1 h at room temperature with 1:100 Alexa Fluor 488 (Life
Technologies, Carlsbad, CA, USA) followed by mounting with Pro Long Gold Antifade
Reagent with 40,6-diamidino-2-phenylindole, DAPI (Invitrogen). Images were acquired
on a Leica DM 4000B fluorescence microscope (Leica Microsystems, Wetzlar,
Germany) and captured with a Leica DFC 300 FX camera (Leica Microsystems).
Cell apoptosis flow cytometry assay. Apoptosis was measured in
1 × 105 hASCs (lean- and obese-isolated hASCs) after the specified treatments.
Cells were collected by trypsinization, washed with PBS and resuspended in 100 μl
1 × binding buffer. Annexin V staining was accomplished following the product
instructions for the FITC Annexin V/Death Cell apoptosis Kit for flow cytometry
(Life Technologies) on a FACSAria III flow cytometer (BD Biosciences, San Jose,
CA, USA) with BD FACSDiva software.
Bisulfite conversion and direct sequencing. Bisulfite conversion was
performed using 200 ng of DNA with the EZ DNA Methylation-Gold Kit
(ZymoResearch, Orange, CA, USA). Converted DNA was eluted in 30 μl. Bisulfite
sequencing was performed following Clark´s procedure.65,66 Briefly, for each region of
interest, PCR amplification was first performed on 1 μl of bisulfite-treated DNA using
conventional PCR. The PCR product was directly used as a template for nested PCR
according to each specific primer set. Samples were purified with the JETQuick PCR
Spin Kit (Genomed, St. Louis, MO, USA) and sequenced with a specific primer by the
sequencing service of GATC Biotech. Briefly, to assess the DNA methylation state of
each cytosine, the raw sequencing electropherograms were analyzed with Geospiza
FinchTV software (Perkin Elmer, Cleveland, OH, USA). The height of each peak was
measured to assess the proportion of each population. For the sake of simplicity, the
methylation level was ranked in five different intervals 0–0.2, 0.21–0.4, 0.41–0.6, 0.61–0.8
and 0.81–1, which reflected the DNA methylation state of the particular cytosine.
Statistical analyses. Statistical analysis was performed with the Statistical
Package for the Social Sciences software, version 15 (SPSS). For in vitro data,
experimental results are presented as mean±S.E.M. from three to four
independent experiments performed at least in duplicate. Statistical significance
was tested by unpaired Student’s t-test or one-way ANOVA followed by the
protected least-significant different test. For clinical and anthropometrical variables,
normal distributed data are expressed as mean value± S.D., and for variables with
no Gaussian distribution values are expressed as median (interquartile range). For
analysis of expression variables that do not have a Gaussian distribution, values
were analyzed by non-parametrical tests. Differences in clinical variables, laboratory
parameters or expression variables between groups were compared by ANOVA with
post hoc Scheffe correction. Interactions between factors as well as the effects of
covariates and covariate interactions with factors were assessed by Spearman’s
correlation analysis. Correction for confounding and interacting variables was
performed using stepwise multiple linear regression analysis.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. The Simpson-Golabi-Behmel Syndrome (SGBS)
preadipocyte cell line was kindly provided by Dr. Wabitsch (University of Ulm,
Germany) and was used as a cellular model of human subcutaneous adipocytes.
Adenoviruses expressing wild type or dominant-negative survivin were kindly
provided by Dr. Altieri (Wistar Institute). This study was supported by grants from the
Spanish Ministry of Economy and Competitiveness and the European Regional
Development Fund (ERDF) (JV: PI14/00228; SF-V: SAF2015-65019R). The Spanish
Biomedical Research Center in Diabetes and Associated Metabolic Disorders
(CIBERdem) (CB07708/0012) an initiative of the Instituto de Salud Carlos III. SF-V
acknowledges support from the Miguel Servet ternure-track program (CP10/00438
and CPII16/00008) from the Fondo de Investigación Sanitaria (FIS) co-financed by
the ERDF. JV and SF-V are the guarantors of this work.
Author contributions
ME, VC-M, CS, GP, MT, CNR and EC carried out the experiments and generated
data. YNA and MAP carried out sequencing analysis. WOO and FT carried out part of
the study selection and human samples processing. JV and SF-V conceived the
study, discussed data and wrote the manuscript. JV and SF-V are the guarantors of
this work and, as such, had full access to all the data in the study and take
responsibility for the integrity of the data and the accuracy of the data analysis.
1. Apovian CM. The clinical and economic consequences of obesity. Am J Manag Care 2013;
19(Suppl): s219–s228.
2. Rodriguez A, Ezquerro S, Mendez-Gimenez L, Becerril S, Fruhbeck G. Revisiting the
adipocyte: a model for integration of cytokine signaling in the regulation of energy
metabolism. Am J Physiol Endocrinol Metab 2015; 309: E691–E714.
3. Lofgren P, Andersson I, Adolfsson B, Leijonhufvud BM, Hertel K, Hoffstedt J et al. Long-term
prospective and controlled studies demonstrate adipose tissue hypercellularity and relative
leptin deficiency in the postobese state. J Clin Endocrinol Metab 2005; 90: 6207–6213.
4. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O et al.
Dynamics of fat cell turnover in humans. Nature 2008; 453: 783–787.
5. Anastasiou CA, Karfopoulou E, Yannakoulia M. Weight regaining: from statistics and
behaviors to physiology and metabolism. Metabolism 2015; 64: 1395–1407.
6. Sassmann-Schweda A, Singh P, Tang C, Wietelmann A, Wettschureck N, Offermanns S.
Increased apoptosis and browning of TAK1-deficient adipocytes protects against obesity.
JCI Insight 2016; 1: e81175.
7. Teoh SL, Das S. Tumour biology of obesity-related cancers: understanding the molecular
concept for better diagnosis and treatment. Tumour Biol 2016; 37: 14363–14380.
8. Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two.
Curr Opin Pharmacol 2016; 29: 77–89.
9. Ilmer M, Vykoukal J, Recio Boiles A, Coleman M, Alt E. Two sides of the same coin: stem
cells in cancer and regenerative medicine. FASEB J 2014; 28: 2748–2761.
10. Donohoe CL, Lysaght J, O'Sullivan J, Reynolds JV. Emerging concepts linking obesity with
the hallmarks of cancer. Trends Endocrinol Metab 2016; 28: 46–62.
11. Pachon-Pena G, Serena C, Ejarque M, Petriz J, Duran X, Oliva-Olivera W et al. Obesity
determines the immunophenotypic profile and functional characteristics of human
mesenchymal stem cells from adipose tissue. Stem Cells Transl Med 2016; 5: 464–475.
12. Altieri DC. Survivin —the inconvenient IAP. Semin Cell Dev Biol 2015; 39: 91–96.
13. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues.
Mol Cancer Ther 2006; 5: 1087–1098.
14. Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK et al. Survivin
upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced
migration of breast carcinoma cells. Endocr-Relat Cancer 2011; 18: 413–428.
15. Palianopoulou M, Papanikolaou V, Stefanou N, Tsezou A. The activation of leptin-mediated
survivin is limited by the inducible suppressor SOCS-3 in MCF-7 cells. Exp Biol Med 2011;
236: 70–76.




Age, years 39±2.54 31±3.34
BMI, kg/m2 22.35±0.77 33.6±1.05*
Abbreviation: BMI, body mass index
Data are presented as mean±S.D. Differences were analyzed by the unpaired
t-test (normal distribution). *Indicates significant difference versus lean
Po0.001
Survivin in obesity
M Ejarque et al
11
Cell Death and Disease
16. Fukuda S, Foster RG, Porter SB, Pelus LM. The antiapoptosis protein survivin is associated
with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and
proliferation of mouse hematopoietic progenitor cells. Blood 2002; 100: 2463–2471.
17. Wang Z, Fukuda S, Pelus LM. Survivin regulates the p53 tumor suppressor gene family.
Oncogene 2004; 23: 8146–8153.
18. Alkhouri N, Gornicka A, Berk MP, Thapaliya S, Dixon LJ, Kashyap S et al. Adipocyte
apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem
2010; 285: 3428–3438.
19. Tinahones FJ, Coin Araguez L, Murri M, Oliva Olivera W, Mayas Torres MD, Barbarroja N
et al. Caspase induction and BCL2 inhibition in human adipose tissue: a potential relationship
with insulin signaling alteration. Diabetes Care 2013; 36: 513–521.
20. Nabilsi NH, Broaddus RR, Loose DS. DNA methylation inhibits p53-mediated survivin
repression. Oncogene 2009; 28: 2046–2050.
21. Huang J, Lyu H, Wang J, Liu B. MicroRNA regulation and therapeutic targeting of survivin
in cancer. Am J Cancer Res 2015; 5: 20–31.
22. Yu X, Zhang X, Dhakal IB, Beggs M, Kadlubar S, Luo D. Induction of cell proliferation and survival
genes by estradiol-repressed microRNAs in breast cancer cells. BMC Cancer 2012; 12: 29.
23. Ceperuelo-Mallafre V, Duran X, Pachon G, Roche K, Garrido-Sanchez L, Vilarrasa N et al.
Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin
resistance. J Clin Endocrinol Metab 2014; 99: E908–E919.
24. Altieri DC. Targeting survivin in cancer. Cancer Lett 2013; 332: 225–228.
25. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway
regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 2000; 113(Pt 23):
4363–4371.
26. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB inducers upregulate cFLIP, a
cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001; 21:
3964–3973.
27. Oksvold MP, Pedersen NM, Forfang L, Smeland EB. Effect of cycloheximide on epidermal
growth factor receptor trafficking and signaling. FEBS Lett 2012; 586: 3575–3581.
28. Wang Q, Sun SY, Khuri F, Curran WJ, Deng X. Mono- or double-site phosphorylation
distinctly regulates the proapoptotic function of Bax. PLoS ONE 2010; 5: e13393.
29. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, Hannink M. Ubiquitination of Keap1, a
BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a
proteasome-independent pathway. J Biol Chem 2005; 280: 30091–30099.
30. Perez LM, Bernal A, de Lucas B, San Martin N, Mastrangelo A, Garcia A et al. Altered
metabolic and stemness capacity of adipose tissue-derived stem cells from obese mouse
and human. PLoS ONE 2015; 10: e0123397.
31. Oliva-Olivera W, Leiva Gea A, Lhamyani S, Coin-Araguez L, Alcaide Torres J, Bernal-Lopez
MR et al. Differences in the osteogenic differentiation capacity of omental adipose-derived
stem cells in obese patients with and without metabolic syndrome. Endocrinology 2015; 156:
4492–4501.
32. Serena C, Keiran N, Ceperuelo-Mallafre V, Ejarque M, Fradera R, Roche K et al.Obesity and
type 2 diabetes alters the immune properties of human adipose derived stem cells. Stem
Cells 2016; 34: 2559–2573.
33. Jiang Y, Qiao H, Liu M, Li Q, Sun Y, Zhang J. Leptin induced apoptosis in rat adipose-derived
stem cells cultured in vitro. Sheng Wu Gong Cheng Xue Bao 2008; 24: 1216–1220.
34. Gullicksen PS, Hausman DB, Dean RG, Hartzell DL, Baile CA. Adipose tissue cellularity and
apoptosis after intracerebroventricular injections of leptin and 21 days of recovery in rats. Int
J Obes Relat Metab Disord 2003; 27: 302–312.
35. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev
2013; 93: 1–21.
36. Ambati S, Kim HK, Yang JY, Lin J, Della-Fera MA, Baile CA. Effects of leptin on apoptosis
and adipogenesis in 3T3-L1 adipocytes. Biochem Pharmacol 2007; 73: 378–384.
37. Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF. YM-155 potentiates
the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation
in an EGFR-dependent context. Mol Cancer Ther 2013; 12: 326–338.
38. Berry R, Jeffery E, Rodeheffer MS. Weighing in on adipocyte precursors. Cell Metab 2014;
19: 8–20.
39. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006; 207: 12–22.
40. Bernardi S, Zauli G, Tikellis C, Candido R, Fabris B, Secchiero P et al. TNF-related
apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed
mice reducing adiposity and systemic inflammation. Clin Sci 2012; 123: 547–555.
41. Fischer-Posovszky P, Wang QA, Asterholm IW, Rutkowski JM, Scherer PE. Targeted
deletion of adipocytes by apoptosis leads to adipose tissue recruitment of alternatively
activated M2 macrophages. Endocrinology 2011; 152: 3074–3081.
42. Dalmas E, Toubal A, Alzaid F, Blazek K, Eames HL, Lebozec K et al. Irf5 deficiency in
macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during
obesity. Nat Med 2015; 21: 610–618.
43. Onate B, Vilahur G, Ferrer-Lorente R, Ybarra J, Diez-Caballero A, Ballesta-Lopez C et al.
The subcutaneous adipose tissue reservoir of functionally active stem cells is reduced in
obese patients. FASEB J 2012; 26: 4327–4336.
44. Giordano C, Barone I, Vircillo V, Panza S, Malivindi R, Gelsomino L et al. Activated FXR
inhibits Leptin signaling and counteracts tumor-promoting activities of cancer-associated
fibroblasts in breast malignancy. Sci Rep 2016; 6: 21782.
45. Qian H, Azain MJ, Compton MM, Hartzell DL, Hausman GJ, Baile CA. Brain administration of
leptin causes deletion of adipocytes by apoptosis. Endocrinology 1998; 139: 791–794.
46. Della-Fera MA, Li C, Baile CA. Resistance to IP leptin-induced adipose apoptosis caused by
high-fat diet in mice. Biochem Biophys Res Commun 2003; 303: 1053–1057.
47. Gullicksen PS, Della-Fera MA, Baile CA. Leptin-induced adipose apoptosis: implications for
body weight regulation. Apoptosis 2003; 8: 327–335.
48. Friedman JM. Leptin, leptin receptors, and the control of body weight. Nutr Rev 1998; 56
(Pt 2): s38–s46; discussion s54-75.
49. Khan S, Ferguson Bennit H, Asuncion Valenzuela MM, Turay D, Diaz Osterman CJ, Moyron
RB et al. Localization and upregulation of survivin in cancer health disparities: a clinical
perspective. Biologics 2015; 9: 57–67.
50. Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A et al. Plasma-derived
exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS ONE
2012; 7: e46737.
51. Dong H, Qian D, Wang Y, Meng L, Chen D, Ji X et al. Survivin expression and serum levels in
pancreatic cancer. World J Surg Oncol 2015; 13: 189.
52. Galeotti L, Adrian K, Berg S, Tarkowski A, Bokarewa M. Circulating survivin indicates severe
course of juvenile idiopathic arthritis. Clin Exp Rheumatol 2008; 26: 373–378.
53. Fukuda S, Mantel CR, Pelus LM. Survivin regulates hematopoietic progenitor cell
proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood 2004;
103: 120–127.
54. Gurbuxani S, Xu Y, Keerthivasan G, Wickrema A, Crispino JD. Differential requirements for
survivin in hematopoietic cell development. Proc Natl Acad Sci USA 2005; 102: 11480–11485.
55. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer
2008; 8: 61–70.
56. Mera S, Magnusson M, Tarkowski A, Bokarewa M. Extracellular survivin up-regulates
adhesion molecules on the surface of leukocytes changing their reactivity pattern. J Leuk Biol
2008; 83: 149–155.
57. Bikov A, Bocskei R, Eszes N, Bohacs A, Losonczy G, Rigo J et al. Circulating survivin levels
in healthy and asthmatic pregnancy. Reprod Biol Endocrinol 2014; 12: 93.
58. Jutzy JM, Khan S, Asuncion-Valenzuela MM, Milford TA, Payne KJ, Wall NR. Tumor-released
survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro.
Cancer Microenviron 2013; 6: 57–68.
59. Chatzigeorgiou A, Karalis KP, Bornstein SR, Chavakis T. Lymphocytes in obesity-related
adipose tissue inflammation. Diabetologia 2012; 55: 2583–2592.
60. Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin, a key member
of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid
arthritis. Arthritis Res Ther 2005; 7: R349–R358.
61. Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy.
Int J Mol Sci 2014; 15: 2494–2516.
62. Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y et al. Early diagnostic
value of survivin and its alternative splice variants in breast cancer. BMC Cancer 2014;
14: 176.
63. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant
adenovirus. J Clin Invest 2001; 108: 981–990.
64. Serena C, Calvo E, Clares MP, Diaz ML, Chicote JU, Beltran-Debon R et al. Significant
in vivo anti-inflammatory activity of Pytren4Q-Mn a superoxide dismutase 2 (SOD2) mimetic
scorpiand-like Mn (II) complex. PLoS ONE 2015; 10: e0119102.
65. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M. DNA methylation: bisulphite
modification and analysis. Nature Protocols 2006; 1: 2353–2364.
66. Patterson K, Molloy L, Qu W, Clark S. DNA methylation: bisulphite modification and analysis.
J Vis Exp 2011; 56: 3170.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from
the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
Survivin in obesity
M Ejarque et al
12
Cell Death and Disease
